Text Size

Comparison of Buprenorphine and Methadone - 3

This study has been completed.
Sponsor:
Collaborator:
Department of Veterans Affairs
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000334
First received: September 20, 1999
Last updated: June 23, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.


Condition Intervention Phase
Opioid-Related Disorders
 Drug: Buprenorphine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacological Comparison of Buprenorphine and Methadone

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Withdrawal severity
  • Opiate agonist symptoms

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   23 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000334

Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Department of Veterans Affairs
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington DC VA
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000334     History of Changes
Other Study ID Numbers: NIDA-3-0009-3, Y01-3-0009-3
Study First Received: September 20, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Methadone
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics
Antitussive Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on May 19, 2013